Previsão
O preço-alvo médio dos analistas é € 0,37 (-92,24%). A mediana é € 0,37 (-92,24%).
| Comprar |
2 |
| Manter |
0 |
| Vender |
0 |
Discussões na comunidade
Ainda não há nenhuma discussão sobre este ativo.
Iniciar discussãoNotícias Ir para o feed de notícias
BioSig Technologies renamed Streamex Corp after merger and gets new ticker symbol STEX
BioSig Technologies will change its name to Streamex Corp. effective September 12, 2025, following its merger with Streamex Exchange Corporation, and will change its Nasdaq ticker from BSGM to STEX; shareholders do not need to take any action and the CUSIP remains unchanged. The company completed a committed capital raise of about $15 million by selling 3,852,149 common shares at $3.90 per share and intends to use the net proceeds, among other things, to purchase gold bars and for working capital. Authorized common shares were increased from 200 million to 500 million, and through its subsidiary Streamex the company entered a three‑year exclusive partnership with Monetary Metals to tokenize yield‑bearing gold products. Apart from the rebranding, the structure and operating business are to remain unchanged. » Mais em de.investing.com
Streamex teams up with Monetary Metals for tokenized gold product with up to 4% yield
Streamex, a subsidiary of BioSig, obtained exclusive three-year rights to tokenize interest-bearing gold products from Monetary Metals and access to its leasing and bond programs. Investors could therefore earn annual returns of up to 4% on tokenized gold bar products; Streamex will finance at least 10% of the qualifying gold-leasing contracts and receive a revenue-linked share. BioSig also raised about USD 15 million through a public offering, will purchase gold bars and is using the capital increase, while InvestingPro points to weak financial metrics and short-term liquidity shortages. » Mais em de.investing.com
BioSig Technologies: shareholders approve share increase and new board structure
Shareholders of BioSig Technologies voted to increase the authorized common shares from 200 million to 500 million and approved an increase to the long-term incentive plan. They also approved measures to issue common shares and convertible debt in connection with Yorkville and the classification of the board of directors into three classes with staggered three-year terms. The vote on the issuance of about 109,070,079 common shares and one super-voting preferred share related to the Streamex acquisition was deferred pending Nasdaq approval; the meeting will resume on September 26. In addition, BioSig completed an underwritten offering of roughly $15 million and restructured convertible notes with YA II PN, Ltd. (two secured convertible notes of $25 million each, with the option to expand to $50 million). » Mais em de.investing.com
Solana gains major boost as BioSig Technologies tokenizes $1.1 billion in gold on its blockchain
BioSig Technologies will tokenize up to $1.1 billion in physical gold bullion on the Solana blockchain, significantly increasing Solana's real-world asset footprint. This move highlights Solana's technical strengths, such as low fees and high transaction speeds, and positions it as a leader in the growing asset tokenization trend. The development is seen as a strong validation of Solana's capabilities and a potential catalyst for further growth. » Mais em finance.yahoo.com
BioSig Technologies expands Streamex advisory team with Russell Starr and secures growth financing
BioSig Technologies has appointed Russell Starr as a strategic advisor for its subsidiary Streamex Exchange Corporation to advance the tokenization of gold reserves and infrastructure. The company also secured up to $1.1 billion in growth financing to support its gold-backed treasury strategy and expanded its advisory team with additional industry experts. Analysts view the stock positively due to the new strategy and potential market returns, despite the company's continued weak financial position. » Mais em de.investing.com
Dados financeiros
No último trimestre, BIOSIG TECHNOLOG. DL-,001 registou receitas de € 0 e um ganho líquido de -€ 13,28 mi
| (EUR) | setembro de 2025 | YoY |
|---|---|---|
| Receitas | 0 | - |
| Ganho bruto | 0 | - |
| Ganho líquido | -13,28 mi | - |
| EBITDA | -12,66 mi | - |
Dados fundamentais
| Métrica | Valor |
|---|---|
Capitalização bolsista | € 174,19 mi |
Número de ações | 31,33 mi |
Máximo/mínimo de 52 semanas | € 12,86 - € 0,21 |
| Dividendos | Não |
Beta | 1,82 |
PER (PE Ratio) | -0,03 |
PEG (PEG Ratio) | 0,00 |
P/VC (PB Ratio) | 0,42 |
P/V (PS Ratio) | 121,85 |
Perfil da empresa
A BioSig Technologies, Inc., juntamente com as suas subsidiárias, opera como empresa de dispositivos médicos. O produto proprietário da empresa inclui o sistema PURE EP (precise uninterrupted real-time evaluation of electrograms electrophysiology), uma plataforma de processamento de sinal que combina hardware e software para dar resposta a desafios conhecidos associados à aquisição de sinal, permitindo aos eletrofisiologistas visualizar e analisar sinais em tempo real. Também se foca em melhorar a aquisição de sinais intracardíacos e a informação de diagnóstico para os procedimentos de fibrilhação auricular, além de ser concebida para resolver limitações de longa data que atrasam e perturbam os procedimentos de ablação cardíaca por cateter. A empresa tem um acordo de investigação com a Universidade do Minnesota para desenvolver terapias inovadoras para tratar doenças do sistema nervoso simpático; e uma colaboração estratégica com a Mayo Foundation for Medical Education and Research para desenvolver uma solução de software de IA e aprendizagem automática para os sistemas PURE EP. A BioSig Technologies, Inc. foi constituída em 2009 e tem sede em Westport, Connecticut.
| Nome | BIOSIG TECHNOLOG. DL-,001 |
| CEO | Anthony Amato |
| Sede | Los Angeles,
ct EUA |
| Site | |
| Setor | Cuidados de saúde |
| Indústria | Cuidados de saúde: equipamentos e produtos |
| Entrada em bolsa | 31/10/2014 |
| Colaboradores | 5 |
Símbolos de ticker
| Bolsa | Símbolo |
|---|---|
NASDAQ | BSGM |